Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 568.35% | 132.46% | -133.71% | -18.46% | -13.57% |
| Total Depreciation and Amortization | 30.59% | 70.29% | -261.75% | 147.91% | -65.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.42% | 15.26% | 72.76% | 5.60% | 31.37% |
| Change in Net Operating Assets | 1,192.37% | -153.78% | 98.41% | 1,168.18% | -101.33% |
| Cash from Operations | 861.13% | -139.04% | -26.72% | 93.05% | -110.71% |
| Capital Expenditure | 79.34% | 60.55% | 53.55% | 88.65% | -2,803.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.07% | 197.07% | 681.81% | 71.88% | 163.14% |
| Cash from Investing | -104.43% | 196.28% | 659.48% | 71.94% | 162.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 233.09% | 96.06% | -29.62% | -53.04% | 13.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 233.09% | 104.26% | -29.62% | -53.04% | 13.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 681.78% | 54.05% | 143.33% | 75.58% | -84.18% |